UPDATE: UBS Upgrades AbbVie To Buy, Lowers Target To $79 As Firm Notes Co's 'acquisition of AGN leads to a NEWCO generating $20B+ of annual free cash flow growing to a highly compelling, 9% FCF yield in '23E (year of Humira's US patent expiry)'